Company: BDRX
Filing Date: 2025-09-12
Form Type: 424B3
Source: 0001214659-25-013675
Chunk: 17

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-12
Form: 424B3
Chunk 17
---
 from CPRIT and the payment of
eligible R&D expenses. Although the CPRIT grant and R&D supplier contracts are with Emtora, the joint arrangement nature of the
LCA results in Emtora being deemed to be acting as the Company’s agent. Accordingly, the Company recognises 100% of the grant and
100% of the R&D expenditure. The CPRIT grant recognised is on a 1 for 2 match. In accordance with the Company’s accounting policy,
the grant, as it is the re-imbursement of directly related costs, is credited to R&D costs in the same period in The Statements of
Comprehensive Income. The escrow account is recognised within prepayments, CPRIT grant received in advance is recognised within deferred
revenue and any grant not yet received is recognised in accrued income.

In 1H25 the company
recognised R&D costs of £0.5 million (1H24: £0.2 million) on the FAP project, made up of expenditure of £2.6 million
(1H24: £0.5 million) netted against CPRIT grant of £2.1 million (1H24: £0.3 million).

| 17 |

The balances in
relation to the FAP project as at June 30 were as follows:

| Schedule of relation the FAP |     | June 30, 2025 unaudited £’000 |     | June 30, 2024 unaudited £’000 |   |
|:-----------------------------|:----|------------------------------:|:----|------------------------------:|:--|
| Prepayments*                 |     |                         2,751 |     |                         6,114 |   |
| Accrued revenue              |     |                           599 |     |                             - |   |
| Deferred revenue             |     |                             - |     |                        (1,468 | ) |

* prepayment reflects
only the escrow account balance

| 3. | Finance income and expense |

| Schedule of finance income                            |     |                    Six months 
                         ended 
 June 30, 2025 unaudited £’000 |     |                    Six months 
                         ended 
 June 30, 2024 unaudited £’000 |
|:------------------------------------------------------|:----|------------------------------:|:----|------------------------------:|
| Finance income                                        |     |                               |     |                               |
| Interest received on bank deposits                    |